B. Riley Initiates Coverage on 4D Molecular with $37 Target — 267% Upside Potential

4D Molecular’s gene therapy could reduce eye injections for AMD patients. B. Riley sees major upside if Phase 3 results succeed. 4D-150 gene therapy fully funded to H2 2028.